Similar to craft manufacturing of cars before assembly lines, monoclonal antibody production has always been an empirical process, making large-scale, low cost antibody development impossible. To build a standardized, industrial scale monoclonal antibody production platform, Abmart antibody technology researchers have taken a process engineering approach to systematically innovate and optimize the entire antibody process. As shown left, monoclonal production at Abmart is a “learning” assembly line process to continuously improve antigen design rules, production parameters and application optimization by a set of priopetary tools including:

1. • Ab-designer: for designing optimal antigens and production parameters
2. • Ab-assembler: for standardized, high quality production of monoclonal antibodies
3. • Ab-screener: for selecting optimal hybridoma cell lines for various applications
4. • Ab-anaylzer: for analyzing and integrating production data into antibody production principles

For a typical antibody development project, Abmart will design a panel of optimal antigens (peptides and protein fragments) to create a group of optimally immunized animals corresponding broad epitopes for a protein target. A hybridoma library consisting of a few dozen high affinity and high specificity cell lines will be generated. Monoclonal antibodies for Western, IP, IF/ICC, IHC and flow cytometry will be selected from this library with high success rate.

At Abmart, a team of experienced monoclonal antibody gurus, molecular biologists, biochemists, cell biologists, immunologists, computer scientists and engineers are working together to create monoclonal assembly lines capable of making tens of thousands of monoclonal antibodies a year at a fraction of current cost. Our goal is to bring monoclonal antibodies to customer at a production below $1000 in the next 2-3 years.